DMT Therapy Shows Lasting Antidepressant Effects in Landmark Placebo-Controlled Trial
A landmark Phase IIa clinical trial published in Nature Medicine has shown that a single 25-minute intravenous dose of DMT — the psychoactive compound traditionally used in Amazonian ayahuasca ceremonies — produces significant and lasting reductions in depression symptoms, with effects persisting up to six months in some participants.
What Happened
Researchers at Imperial College London, in collaboration with Helus (formerly Cybin UK), conducted a randomized, placebo-controlled trial involving 34 participants with moderate-to-severe depression who had failed at least two prior treatments. Half received a single 21.5mg intravenous dose of synthetic DMT; the other half received a placebo. Both groups received identical psychotherapeutic support before, during, and after dosing.
Who Conducted the Study
The trial was led by Dr. David Erritzoe, Clinical Associate Professor in Psychopharmacology and Psychiatry at Imperial College London's Department of Brain Sciences, in partnership with Helus. Results were published in the peer-reviewed journal Nature Medicine (DOI: 10.1038/s41591-025-04154-z) and reported by The Guardian.
When and Where
The trial was conducted at Hammersmith Medicines Research in London and MAC Clinical Research in Liverpool, with follow-up carried out at Imperial College London's Hammersmith Campus. Findings were published in early 2026.
Why It Matters
Unlike psilocybin or MDMA therapies that require multi-hour sessions, DMT's rapid metabolism allows for a psychedelic experience lasting approximately 25 minutes — drastically reducing cost and clinical resource demands. Participants in the DMT group showed an average 10.8-point greater reduction in depression severity (measured by the MADRS scale) within one week, with benefits sustained at three months and, for some, up to six months. Critically, no serious adverse events were reported.
How It Connects to Ancient Traditions
DMT is the primary psychoactive compound in ayahuasca, a sacred plant medicine used for centuries by Indigenous Amazonian communities for healing and spiritual ceremonies. While traditional ayahuasca is consumed as a brew accompanied by ritual songs and guidance from shamans, the synthetic version eliminates the nausea and vomiting associated with the plant-based preparation while retaining the core psychedelic experience. The study's authors emphasized that the intensity of the acute psychedelic experience correlated with therapeutic efficacy — echoing the Indigenous understanding that the visionary journey itself is central to healing.
"DMT can act as a catalyst," said co-author Tommaso Barba, a PhD candidate at Imperial. "It helps people understand changes they need to make in their mentality or in their life." This framing aligns remarkably well with the traditional view that ayahuasca does not simply "fix" depression but rather opens a door to self-understanding and transformation — a convergence of ancient wisdom and modern clinical science that the researchers themselves acknowledge.
Sources: Erritzoe et al., Nature Medicine (2026) — nature.com/articles/s41591-025-04154-z; The Guardian (February 2026) — theguardian.com; Imperial College London news release — imperial.ac.uk
— Editorial Dept.
#Psychology #IndigenousWisdom #Spirituality